Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly
- Schmid, Herbert A
- Brue, Thierry
- Gadelha, Mônica R
- Shimon, Ilan
- Kapur, Karen
- Pedroncelli, Alberto M
- Fleseriu, Maria
- COLAO, ANNAMARIA
DOIAbstract
The purpose of this study was to gain more insight into the mechanism of action of pasireotide in patients who completed the PAOLA study. PAOLA was a 24-week, Phase III, randomized, three-arm study of pasireotide LAR 40 and 60 mg versus octreotide LAR 30 mg or lanreotide Autogel 120 mg in patients with inadequately controlled acromegaly. The current work was a planned exploratory objective of the PAOLA study that evaluated changes in levels of growth hormone (GH), insulin-like growth factor 1 (IGF-1), IGF-binding proteins (IGFBP-2, IGFBP-3), glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG) in each treatment arm. Responders to pasireotide LAR (mean GH levels <2.5 μg/L and normal IGF-1 levels at 24 weeks) had lower GH and IGF-1 l...